QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

21Jan 2025

New publication on epidemiology and treatment patterns of patients with narcolepsy!

An article using Swedish register data to study epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy is hot off the press.

The study found narcolepsy prevalence to be increasing during the study period, with both prevalence and incidence being higher in females than in males.

At the time of the first narcolepsy diagnosis, not all patients used narcolepsy-related medications, potentially indicating […]

17Jan 2025

Welcome to the team Abraham Choong!

This week we have welcomed Abraham Choong to the Quantify Research team!

Abraham has held progressively senior positions at industry-leading organizations and brings a wealth of experience in account management and business development in the RWD/E sphere.

Abraham will spearhead Quantify’s business development efforts, identifying new opportunities and expanding our client base to further solidify our position in the market.

We are very excited to have […]

16Jan 2025

Are you interested in hearing about the newest developments in industry and academia on Nordic Real World Evidence?

Come and join us for the 5th Nordic RWE and AI conference on 28th-29th January, live in Helsinki, and hosted by the University of Helsinki and Åbo Akademi.

The event involves an interesting mix of how Nordic RWE supports the Life Sciences industry to showcase value, and regulatory decision making to advance patient care.

Among top […]

14Jan 2025

Real-world evidence (RWE) and Clinical Trials: Complementary roles in evidence- based research for all patients

Certain patient groups may be underrepresented or excluded from RCTs due to eligibility criteria, logistical barriers, ethical concerns or other reasons.

Examples of these potential groups are females, pregnant or breastfeeding females, older adults due to age or comorbidities, children, people with rare or orphan diseases, people from underserved or minority communities, non-binary or transgender individuals, people with mental health disorders, and people on polypharmacy.

RWE studies provide opportunities to derive […]